Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

RefSeq allows visualization of splice variants of the two genes annotated in the Hg19 version of the human genome. (D) Within each group of patients defined by either high, low, or intermediate CBX5 levels, the percentage representation of each stage of the MS disease is indicated. (E) Volcano plot illustrating differential gene expression between Hi-CBX5 patients and symptomatic controls. (F) Analysis of genes down-regulated between Hi-CBX5 patients as compared to symptomatic controls using the ChEA (ChIP-seq enrichment analysis) database providing information on transcription factors likely to regulate these genes (VDR, vitamin D receptor). (G) Volcano plot illustrating the differential gene expression between Lo-CBX5 patients and symptomatic controls. (H) Schematic representation of the KEGG ferroptosis pathway.

Source: A subset of MS patients displays extensive transcriptional deregulation in monocytes. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were excluded if they had other neurological diseases or received glucocorticoids within the month preceding sampling.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Defective Integrator activity shapes the transcriptome of patients with multiple sclerosis

Study design awaiting verification · Life Science Alliance · 2024

Original publication title

Defective Integrator activity shapes the transcriptome of patients with multiple sclerosis

Yevheniia Porozhan; Mikkel Carstensen; Sandrine Thouroude; Mickael Costallat; Christophe Rachez; Eric Batsché; Thor Petersen; Tove Christensen; Christian Muchardt

© 2024 Porozhan et al.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

High-depth RNA sequencing reveals down-regulation of HP1α/CBX5 in monocytes of multiple sclerosis patients, associated with major transcriptomic changes and reduced activity of the Integrator complex.

HP1α/CBX5 is an epigenetic regulator with a suspected role in multiple sclerosis (MS). Here, using high-depth RNA sequencing on monocytes, we identified a subset of MS patients with reduced CBX5 expression, correlating with progressive stages of the disease and extensive transcriptomic alterations. Examination of rare non-coding RNA species in these patients revealed impaired maturation/degradation of U snRNAs and enhancer RNAs, indicative of reduced activity of the Integrator, a complex with suspected links to increased MS risk. At protein-coding genes, compromised Integrator activity manifested in reduced pre-mRNA splicing efficiency and altered expression of genes regulated by RNA polymerase II pause: release.

Inactivation of Cbx5 in the mouse mirrored most of these transcriptional defects and resulted in hypersensitivity to experimental autoimmune encephalomyelitis. Collectively, our observations suggested a major contribution of the Integrator complex in safeguarding against transcriptional anomalies characteristic of MS, with HP1α/CBX5 emerging as an unexpected regulator of this complex’s activity. These findings bring novel insights into the transcriptional aspects of MS and provide potential new criteria for patient stratification.

Authors’ abstract

High-depth RNA sequencing reveals down-regulation of HP1α/CBX5 in monocytes of multiple sclerosis patients, associated with major transcriptomic changes and reduced activity of the Integrator complex.

HP1α/CBX5 is an epigenetic regulator with a suspected role in multiple sclerosis (MS). Here, using high-depth RNA sequencing on monocytes, we identified a subset of MS patients with reduced CBX5 expression, correlating with progressive stages of the disease and extensive transcriptomic alterations. Examination of rare non-coding RNA species in these patients revealed impaired maturation/degradation of U snRNAs and enhancer RNAs, indicative of reduced activity of the Integrator, a complex with suspected links to increased MS risk. At protein-coding genes, compromised Integrator activity manifested in reduced pre-mRNA splicing efficiency and altered expression of genes regulated by RNA polymerase II pause: release.

Inactivation of Cbx5 in the mouse mirrored most of these transcriptional defects and resulted in hypersensitivity to experimental autoimmune encephalomyelitis. Collectively, our observations suggested a major contribution of the Integrator complex in safeguarding against transcriptional anomalies characteristic of MS, with HP1α/CBX5 emerging as an unexpected regulator of this complex’s activity. These findings bring novel insights into the transcriptional aspects of MS and provide potential new criteria for patient stratification.

Publication and source details

Original title: Defective Integrator activity shapes the transcriptome of patients with multiple sclerosis

Yevheniia Porozhan; Mikkel Carstensen; Sandrine Thouroude; Mickael Costallat; Christophe Rachez; Eric Batsché; Thor Petersen; Tove Christensen; Christian Muchardt

Life Science Alliance · 2024

Correspondence: christian.muchardt@sorbonne-universite.fr
*

Yevheniia Porozhan and Mikkel Carstensen contributed equally to this work

†

Thor Petersen and Tove Christensen contributed equally to this work

© 2024 Porozhan et al.2024https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). Agence Nationale de la Recherche (ANR)http://dx.doi.org/10.13039/501100001665 REVIVE Muchardt C AU | Sundhedsvidenskabelige Fakultet, Aarhus Universitet (Faculty of Health Sciences, Aarhus University)http://dx.doi.org/10.13039/100012526 Christensen T Scleroseforeningen (Danish MS Society)http://dx.doi.org/10.13039/100008361 Christensen T Beckett-Fonden (Beckett Fund)http://dx.doi.org/10.13039/501100009898 Christensen T Dagmar Marshalls Fond (Dagmar Marshalls Fund)http://dx.doi.org/10.13039/100007403 Christensen T Knud Højgaards Fond (KHF)http://dx.doi.org/10.13039/501100009938 Carstensen M Aage og Johanne Louis-Hansens Fond (Louis-Hansen Fonden)http://dx.doi.org/10.13039/501100010344 Carstensen M Oticon Fonden (Oticon Foundation)http://dx.doi.org/10.13039/501100007696 Carstensen M

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T10:26:02.571351+00:00

DOI: 10.26508/lsa.202402586 · PMC11259605